Drug Profile
Emapalumab - Swedish Orphan Biovitrum
Alternative Names: emapalumab-lzsg; Gamifant; NI-0501Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator NovImmune SA
- Developer Institut Merieux; Swedish Orphan Biovitrum
- Class Monoclonal antibodies
- Mechanism of Action Interferon gamma inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophagocytic lymphohistiocytosis
- Phase II/III COVID 2019 infections
- Phase II Transplant rejection
- No development reported Unspecified
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Japan (IV, Infusion)
- 09 Dec 2023 Efficacy and adverse events data from a phase II/III trial in Haemophagocytic lymphohistiocytosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 31 May 2023 Efficacy and adverse events data from phase-III EMERALD trial in Haemophagocytic lymphohistiocytosis presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)